We are live on ! Find out more
STLN

Starling Oncology
STLN

49 hedge funds and large institutions have $205M invested in Starling Oncology in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

111% more capital invested

Capital invested by funds: $97.2M → $205M (+$108M)

41.79% more ownership

Funds ownership: 40.75% → 82.55% (+42%)

29% more funds holding

Funds holding: 38 → 49 (+11)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

Holders
49
Holders Change
+11
Holders Change %
+28.95%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
6
Reduced
11
Closed
5
Calls
$656K
Puts
–
Net Calls
+$656K
Net Calls Change
-$82K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$56.2M
2
SRCM
Sage Rock Capital Management
New York
+$10.5M
3
MF
Magnetar Financial
Illinois
+$9.23M
4
ECM
Element Capital Management
New York
+$8.75M
5
PWAM
Park West Asset Management
California
+$3.7M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$3.05M
2
FTCM
Fir Tree Capital Management
New York
-$2.59M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.03M
4
SCM
Saba Capital Management
New York
-$828K
5
AGM
Alpine Global Management
New York
-$664K

STLN Hedge Fund Activity: Q4 2020 in Review

49 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q4 2020, worth a combined $205M — up 111% from $97.2M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new STLN positions and 5 closed out — a net gain of 11 holders — while 6 added to existing stakes and 11 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $56.2M. The largest seller was UBS O'Connor, cutting an estimated $3.05M.

  • 49 institutional investors held Starling Oncology (STLN) as of Q4 2020, up from 38 in Q3 2020.
  • Funds reported $205M of Starling Oncology stock for Q4 2020, up 111% quarter-over-quarter.
  • 16 funds opened new Starling Oncology positions in Q4 2020 and 5 closed out, a net change of +11 holders.
  • The largest Starling Oncology buyer in Q4 2020 was Deerfield Management, an estimated $56.2M added.
  • The largest Starling Oncology seller in Q4 2020 was UBS O'Connor, an estimated $3.05M sold.

Based on aggregated 13F filings for Q4 2020.